In a mouse study, Bifidobacterium longum subsp. longum reduced chemotherapy-related weight loss, diarrhea, and gut inflammation, while B. bifidum and B. adolescentis were linked to poorer outcomes, according to research reviewed by Gram. The findings suggest that the specific probiotic species matters when protecting the gut during cancer treatment.
Chemotherapy can damage the lining of the gut, causing weight loss, diarrhea, and inflammation that make treatment harder to finish. A new study in Food & Function tested six types of Bifidobacterium, a beneficial bacteria often sold as probiotics, in mice given the chemotherapy drug 5-fluorouracil. One species, Bifidobacterium longum subsp. longum, reduced weight loss, eased diarrhea, calmed gut inflammation, and shifted the gut microbiome in helpful ways. Two other species, B. bifidum and B. adolescentis, were linked to poorer outcomes. According to research reviewed by Gram, the results suggest that the specific probiotic strain matters. Because this work was done in mice, it does not yet show how these effects would work in people.
Key Statistics
A 2026 study published in Food & Function found that Bifidobacterium longum subsp. longum reduced weight loss, eased diarrhea, and lowered gut inflammation in mice treated with the chemotherapy drug 5-fluorouracil, compared with other probiotic species tested.
In the same 2026 study, mice given Bifidobacterium bifidum or Bifidobacterium adolescentis showed lower survival and less favorable gut outcomes than mice given Bifidobacterium longum subsp. longum.
The Quick Take
- What they studied: Researchers wanted to know whether different types of Bifidobacterium, a common probiotic bacteria, protect the gut from damage caused by a chemotherapy drug, and which types work best.
- Who participated: The study used laboratory mice that were given a chemotherapy drug called 5-fluorouracil to damage their intestines. The exact number of mice was not stated in the summary provided.
- Key finding: Bifidobacterium longum subsp. longum helped mice lose less weight, eat more normally, and have less diarrhea, with less gut inflammation. Two other species, B. bifidum and B. adolescentis, were linked to lower survival and worse gut outcomes.
- What it means for you: This research suggests that not every probiotic offers the same benefit during chemotherapy. Anyone considering a probiotic during cancer treatment should talk with their oncology team first, since these results come from animal testing and are not yet proven in people.
The Research Details
The researchers first created a mouse model of gut damage by giving mice 5-fluorouracil, a chemotherapy drug that can harm the intestinal lining. This setup allowed them to copy the kind of digestive trouble people often experience during cancer treatment.
Next, the team gave different groups of mice one of six edible Bifidobacterium species and then compared how each group fared. They tracked body weight, how much the mice ate, diarrhea, survival, markers of gut barrier health and inflammation, the makeup of gut bacteria, and levels of bile acids, which are substances that help digest fat and can influence the gut.
Finally, the researchers ran additional experiments using bacteria known to break down mucin, a protective mucus layer in the gut. This helped them test whether the ability to feed on that mucus explained the differences between species. It did not fully explain them.
Comparing six species side by side makes it possible to see which ones actually help, rather than assuming all probiotics work the same way. Using a controlled animal model also lets researchers keep conditions consistent and measure gut changes in detail that would be hard to track in people.
The study was published in a peer-reviewed journal, which means outside experts reviewed it before publication. It measured many outcomes, including weight, survival, gut tissue, and gut bacteria, which strengthens the picture. However, the summary does not state how many mice were used, and animal results do not always translate to humans. The journal’s impact factor was not provided in the source material.
What the Results Show
The most notable result was that Bifidobacterium longum subsp. longum, often shortened to BLL, reduced the weight loss that 5-fluorouracil usually causes in mice. The mice also ate more food than untreated chemotherapy mice, which suggests they felt better overall.
BLL also appeared to ease diarrhea, a common and distressing side effect of chemotherapy. Researchers saw improved expression of genes linked to the gut lining, which suggests the intestinal barrier was better protected. Inflammation in the colon tissue was also reduced.
The benefits seemed connected to changes in the gut microbiome, the community of bacteria living in the digestive tract. Specific bacterial groups, including Enterococcus, Ruminococcaceae UCG_014, and Ruminococcus 2, shifted in abundance. Levels of cholic acid and deoxycholic acid, two bile acids, also changed, which may help explain how the probiotic worked.
In contrast, B. bifidum and B. adolescentis were associated with lower survival and less favorable gut outcomes. This suggests that a probiotic can be harmful or unhelpful, not just neutral, depending on the species.
The researchers found that the ability of a bacterium to use mucin, the protective mucus in the gut, did not fully explain why some species helped and others did not. This means scientists cannot yet predict a probiotic’s effect just by checking how well it feeds on mucus. The result points to other factors, possibly including how the bacteria interact with the gut community and its chemistry.
Earlier research has generally suggested that Bifidobacterium species may support gut health, but many studies have tested only one species or grouped several together. This study adds value by comparing six species directly under the same conditions, which helps explain why probiotic results can vary so widely. It is consistent with a growing view that probiotic benefits are strain-specific.
The most important limitation is that this research was done in mice, not people. Mouse digestive systems and gut bacteria differ from human ones, so the same effects may not appear in patients. The summary also does not report the number of animals used, which makes it harder to judge how strong the statistical evidence is. Finally, the study tested one chemotherapy drug, so results may not apply to other cancer treatments or to people with different diets and medical histories.
The Bottom Line
Research shows that in mice, one species, Bifidobacterium longum subsp. longum, protected against chemotherapy-related gut damage, while two other species did not. Confidence in these animal findings is moderate, since they have not been tested in human clinical trials. Anyone considering a probiotic during chemotherapy should ask their care team which specific strain, if any, is appropriate.
People receiving chemotherapy with 5-fluorouracil, their caregivers, oncology nurses, dietitians, and researchers developing probiotic products may find this study useful. Healthy people looking for general gut support should not assume these results apply to them, and people with weakened immune systems should be especially careful about adding any probiotic without medical advice.
Human studies would need to be run before any benefit could be confirmed, and that process often takes several years. Even if future trials are positive, changes in symptoms like diarrhea or appetite would be expected to show up during treatment cycles rather than overnight, and results vary from person to person.
Frequently Asked Questions
Can probiotics help protect the gut during chemotherapy?
Animal research suggests certain probiotics may help. A 2026 mouse study found that Bifidobacterium longum subsp. longum reduced chemotherapy-related weight loss and diarrhea, but human trials are still needed before this can be recommended for patients.
Are all Bifidobacterium probiotics equally effective?
No, research shows they are not. In a mouse study comparing six Bifidobacterium species, only Bifidobacterium longum subsp. longum showed clear protective benefits, while B. bifidum and B. adolescentis were linked to lower survival and worse gut outcomes.
What does 5-fluorouracil do to the gut?
5-fluorouracil is a chemotherapy drug that can damage the intestinal lining, leading to weight loss, reduced appetite, diarrhea, and inflammation. Researchers use it in mouse models to study how gut damage develops and how potential treatments may help.
Should I take a probiotic during chemotherapy?
Talk with your oncology team before starting any probiotic during chemotherapy. Strains differ in effect, and some may not be suitable for people with weakened immune systems, so your care team can advise which product, if any, is safe for you.
Want to Apply This Research?
- Log daily bowel movements on a 1 to 7 stool consistency scale, number of loose stools per day, and daily food intake in a simple percentage of usual meals. Share these logs with your care team to spot patterns during chemotherapy cycles.
- Set a reminder to log symptoms each evening and to ask your care team about probiotics before starting any new supplement. Keep a record of the exact product name and strain listed on the label, since this study showed that different species can have very different effects.
- Track weekly weight, hydration, appetite, and digestive symptoms across each chemotherapy cycle and recovery period. Review trends with your oncology team to determine whether any supplement is helping, and update the log whenever a medication or probiotic changes.
This article summarizes a laboratory study conducted in mice and is not medical advice. Results from animal research do not always apply to humans. Anyone undergoing chemotherapy or considering a probiotic should consult their oncologist, registered dietitian, or healthcare provider before making changes to their treatment or supplements.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.